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Abstract
Background: Equitable access to affordable medicines and diagnostic tests is an integral component of optimal
clinical care of patients with asthma and chronic obstructive pulmonary disease (COPD). In Uganda, we lack
contemporary data about the availability, cost and affordability of medicines and diagnostic tests essential in
asthma and COPD management.
Methods: Data on the availability, cost and affordability of 17 medicines and 2 diagnostic tests essential in asthma and
COPD management were collected from 22 public hospitals, 23 private and 85 private pharmacies. The percentage of
the available medicines and diagnostic tests, the median retail price of the lowest priced generic brand and affordability
in terms of the number of days’ wages it would cost the least paid public servant were analysed.
Results: The availability of inhaled short acting beta agonists (SABA), oral leukotriene receptor antagonists (LTRA),
inhaled LABA-ICS combinations and inhaled corticosteroids (ICS) in all the study sites was 75%, 60.8%, 46.9% and 45.4%
respectively. None of the study sites had inhaled long acting anti muscarinic agents (LAMA) and inhaled long acting
beta agonist (LABA)-LAMA combinations. Spirometry and peak flow-metry as diagnostic tests were available in 24.4%
and 6.7% of the study sites respectively. Affordability ranged from 2.2 days’ wages for inhaled salbutamol to 17.1 days’
wages for formoterol/budesonide inhalers and 27.8 days’ wages for spirometry.
Conclusion: Medicines and diagnostic tests essential in asthma and COPD care are not widely available in Uganda and
remain largely unaffordable. Strategies to improve access to affordable asthma and COPD medicines and diagnostic
tests should be implemented in Uganda.
Keywords: Access, Medicines, Diagnostic tests, Asthma, COPD, Sub Saharan Africa, Uganda
Background
Globally, chronic respiratory diseases pose a major
public health threat. Notably, the burden of asthma and
chronic obstructive pulmonary disease (COPD) is stead-
ily increasing in both developed and developing coun-
tries. According to recent World Health Organisation
(WHO) estimates, about 235 million people have asthma
and 65 million people have moderate to severe
COPD. High rates of mortality due to both conditions
have been documented in low-and middle income
countries (LMIC). In 2012, > three million people
died of COPD, which accounted for about 6% of the
all the deaths globally. An estimated 90% of these
deaths occurred in LMIC [1].
In Uganda, a similar growing trend of mortality related
to asthma and COPD has been described. A descriptive
retrospective study conducted at an urban national refer-
ral hospital reported the burden of asthma and COPD of
70.6% and 21.6% respectively in 558 patients admitted to
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the hospital’s adult pulmonology unit between December
2010 and August 2011. In hospital mortality among the
patients admitted with asthma and COPD was 8.3% and
9.3% respectively [2]. Another population based pro-
spective cross sectional study performed in rural
Masindi, a district in Western Uganda in 2012 reported
the burden of COPD of 16.2% especially among partici-
pants of both gender aged 30–39 years [3]. This high-
lights that the COPD in Uganda primarily occurs among
the young and this could probably be due to effects of
environmental factors like increased use of biomass fuel
for cooking and early infections like tuberculosis and re-
current childhood pneumonia. The first and recently
concluded nationwide population survey to determine
the burden and predictors of asthma in Uganda, the
Uganda National Asthma Survey (UNAS) has docu-
mented a prevalence of 9.8% with a higher prevalence of
asthma reported in urban areas compared to rural areas
(Kirenga B et al. Unpublished data, 2016).
Despite the increasing burden of asthma and COPD
and related high mortality rates in LMIC, suboptimal
care of patients with asthma and COPD is still very
common in LMIC. The challenges of low availability of
affordable medicines and diagnostic tests for asthma and
COPD, poor health system structures coupled with low
knowledge levels of asthma and COPD management
among healthcare workers and patients contribute to the
suboptimal care in LMIC [4–8].
The WHO strategy on secondary and tertiary preven-
tion section of chronic respiratory diseases emphasises
the need to strengthen health care by identifying cost-
effective interventions, upgrading standards and accessi-
bility of care at different levels of the health care system
and improving access to affordable medicines [9].
Improving access to affordable medicine is one of the
key components of the millennium development goals
(MDG) referred to as the MDG target 8E [10].
The main objective of this study was to provide
contemporary information about the availability, cost
and affordability of selected essential medicines and
diagnostic tests for asthma and COPD in Uganda, as
recommended by the Global INitiative for Asthma
(GINA) guidelines [11], Global initiative for chronic
Obstructive Lung Disease (GOLD) guidelines [12],
WHO guidelines of asthma and COPD management
and are included in the WHO essential drug list for
management of asthma and COPD [1, 13] and
Uganda Clinical Guidelines (UCG).
This data will help guide a pragmatic approach to ad-
dress the low access to affordable asthma and COPD
medicines and diagnostic tests. It will also guide health-
care managers in Uganda on resource mobilisation and
allocation for essential medicines and diagnostic tests for
asthma and COPD. The data obtained will add to the
existing literature on extent of availability, cost and af-
fordability of essential asthma and COPD medicines and
diagnostic tests in LMIC.
Methods
Study settings and selection of study sites
This was a cross sectional study that was conducted
from 15th January 2017 to 28th February 2017 in 23
public hospitals, 22 private hospitals and 85 privately
owned pharmacies that were randomly selected from the
4 regions of Uganda. The central, eastern, western and
northern regions accounted for 55.4%, 20%, 16.2% and
8.4% of the selected study sites respectively (Fig. 1 shows
geographical location of the study sites).
All the selected hospitals were tertiary hospitals,
served a significantly large local population in each geo-
graphical location and had a daily or weekly functioning
outpatient general medical or respiratory clinic. None
was a specialist hospital. The pharmacies selected were
those in close proximity to a tertiary hospital or a health
centre IV (secondary hospital) serving a large local
population and are licensed by the regulatory body
(National Drug Authority) to sell all classes of
medicines.
A total of 2 public and 2 private hospitals were ex-
cluded because they lacked a regular outpatient medical
specialist clinic. Drug shops were not included because
they are not licensed to sell essential medicines for
NCD. A total of 30 pharmacies were excluded because
the staff declined to provide the desired information on
availability and cost of the study drugs.
According to the registry of ministry of Health, Republic
of Uganda, there are 2 national referral hospitals, 14 re-
gional referral hospitals and 139 general hospitals. About
41.9% are government owned, 40.7% are private not for
profit (PNFP) and 17.4% are private for profit [14].
Medical care in the public hospitals is paid for the
government of Uganda. A national procurement institu-
tion called the National Medical Stores (NMS) is consti-
tutionally mandated to procure and distribute all drugs
and diagnostic tests for all government hospitals. Despite
this, stock out of drugs and diagnostic tests is a common
finding in most public hospitals. Patients seek medical
care from private hospitals and pharmacies as a second
option in cases of unavailability of drugs and diagnostic
tests. These procure their drugs and diagnostic tests
from private companies. According to 2016/17 Uganda
National Household Survey (UNHS) conducted by the
Uganda Bureau of Statistics (UBOS) to collect informa-
tion on socio-economic characteristics at both house-
hold and community levels with an aim of monitoring
development performance of key sectors, about 48% and
34% of surveyed participants sought medical care from
private clinics/hospitals and public hospitals respectively.
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Patients also sought medical care from private pharma-
cies and village health workers [15].
About 599 privately owned retail pharmacies and 90
private hospital pharmacies that sell human pharma-
ceutical drugs are registered by the National Drug
Authority. About more than 70% of these are in the
central region [16].
This study was conducted as a sub-section of the large
study called the Access to Cardiovascular diseases,
Chronic Obstructive pulmonary disease, Diabetes mellitus
and Asthma Drugs and diagnostics (ACCODAD) study
that assessed the availability and affordability of essential
medicines and diagnostic tests of non-communicable dis-
eases (NCD) in Uganda. The first published study from
the ACCODAD study assessed access to key drugs and
diagnostic tests in the management of diabetes and
cardiovascular diseases [17].
Sample size estimation
Basing on one of the primary objectives of the ACCO-
DAD study which was to determine the extent of
availability of the medicines and diagnostic tests of
interest, the overall availability of Pulmicort® (budeso-
nide) in a study by Babar Z et al. in 52 surveyed LMICs
of 8.3% was used as the prevalence (P) [7]. Using the
formula: n = Z2 P (1-P)/d2 where Z (normal value
corresponding to the 95% confidence interval) =1.96, P
= 0.083 and d = 0.05 (desired precision of estimation), a
sample size of 117 healthcare units (public and private
hospitals and private pharmacies) was obtained. We
increased the sample size of the surveyed health units to
130 to generate adequate information. We aimed at sur-
veying a minimum of 10% of the registered public and
private hospitals and private pharmacies in Uganda.
Data collection
Data was collected using a pre tested questionnaire
based on the WHO and Health Action International
(HAI) standardised methods of assessing medicine avail-
ability, prices and affordability in LMIC [18] from 15th
January 2017 to 28th February 2017. The study data
collection team underwent a brief training before com-
mencement of the study to improve quality and stand-
ardisation of data.
The diagnostic tests of interest of asthma and COPD
in this study were spirometry and peak flow-metry. The
medicines of interest were: inhaled short acting beta ag-
onists (SABA) like salbutamol meter dose inhaler (MDI)
100 μg, inhaled short acting anti muscarinic agents
(SAMA) like ipratropium bromide 20 and 40 μg MDI,
inhaled long acting anti muscarinic agents (LAMA) like
tiotropium 18 μg dry powder inhalers (DPI), inhaled
SABA and SAMA combinations like salbutamol/ipratro-
pium 100/20 μg soft mist inhaler (SMI), inhaled LABA
and LAMA combinations like olodaterol/tiotropium 5/
5 μg SMI, inhaled LABA-inhaled corticosteroid (ICS)
combinations like formoterol-budesonide 4.5/160 μg
MDI and salmeterol-fluticasone propionate 25/125 μg
MDI, ICS like budesonide 200 μg DPI and fluticasone
propionate 250 μg DPI, oral methylxanthines like slow
Fig. 1 Geographical location of the selected study sites. Map of Uganda obtained from Wikimedia
Commons. https://commons.wikimedia.org/wiki/Maps_of_Uganda#/media/File:Ug-map.png
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release theophylline 100 mg and oral leukotriene recep-
tor antagonists (LTRA) like tablets montelukast 10 mg
and 20 mg. Adult and paediatric spacer devices were
also included due to their integral role in asthma and
COPD management especially in young children and
elderly patients.
Information about the availability of each stated medi-
cine category and monthly cost of the available lowest
priced generic medicine was obtained. The cost of the
medicines obtained was the retail prices charged directly
to the patients at the respective pharmacies of the pri-
vate hospitals and private pharmacies. Information about
the availability and cost of the diagnostic tests of interest
was only obtained from the hospitals.
The cost of the medicines in the public hospitals was
not obtained since medical care is offered free of charge.
All the costs of the medicines and the diagnostic tests
were obtained in Uganda shillings (UgX) and converted
to US dollars (USD) according to the existing exchange
rate at the time of data collection (1 USD = 3600 UgX).
Data analysis
Availability of the medicine categories were assessed
using simple descriptive statistics by calculating the pro-
portions of hospitals and private pharmacies in which
any type and dose of the medicine and diagnostic test
was present on the day of data collection at the study
site. The study definition of low, moderate and high
availability of the selected medicines and diagnostic tests
at any study site was <50%, 50–79% and ≥80% respect-
ively. The availability of the selected diagnostic tests and
medicines was compared between the study sites and
study regions using chi-square test to determine signifi-
cant differences. A p value of <0.05 was considered as
statistically significant.
The unit prices of the medicines in USD were con-
verted to a median price ratio (MPR) by dividing the
median local price by an international reference price
(IRP). The IRP is obtained from the Management
Sciences for Health International Drug Price Indicator
Guide which reports median prices of high quality mul-
tisource medicines offered to LMICs countries by differ-
ent suppliers. The MPR is used to express how much
greater or less the median local medicine price is than
the IRP. An MPR of 3 would mean that the local medi-
cine price is three times greater than the IRP. The study
definition of reasonable pricing was when the MPR of a
patient’s medicine was <1.5 [19]. The cost of the avail-
able lowest priced generic medicine was compared to
the cost of the available originator brand medicine.
Affordability was estimated using the median monthly
medicine prices and the average salary of the lowest paid
government worker in USD and calculating the number
of days’ wages required to purchase a one-month course
of treatment or to pay for a specific diagnostic test.
Medicines and diagnostic tests that cost ≤3 days’ wages
were considered affordable.
The lowest paid skilled government worker at the time
of the study (scale U8 lower-non formal education
teachers) earns a gross salary of 198,793 UgX equivalent
to 55.2 USD. After tax deductions, this translates to a
net salary of 139,155 UgX equivalent to 38.7 USD per
month or 4638.5 UgX (1.3 USD daily) [20].
Results
Availability of the medicines and diagnostic tests
The availability of the selected medicines ranged from
0% for inhaled LAMA and inhaled LAMA-LABA
combinations to 75% for SABA. Inhaled SABA-SAMA
combinations, inhaled SAMA, oral methylxanthines,
ICS, LABA-ICS and oral LTRA were available in 10.8%,
12.3%, 16.9%, 45.4%, 46.9% and 60.8% respectively in all
study sites. Adult and paediatric spacers were available
in only 18.5% and 19.2% of study sites respectively.
Spirometry and peak flow-metry were available in only
24.4% and 6.7% of the study sites respectively (sum-
marised in Table 1).
Comparison of the availability of selected medicines in
the study sites and regions
There was a stark difference in availability of medicines
in the study sites and regions. Low availability of medi-
cines was mostly documented in the public hospitals
compared to private hospitals and pharmacies. The only
available medicines in the public hospitals were: inhaled
SABA in 26.1% compared to 77.3% and 88.2% in private
hospitals and pharmacies respectively (p < 0.001), ICS in
4.4% compared to 50% and 55.3% in private hospitals
and pharmacies respectively (p < 0.001) and oral methyl-
xanthines in 4.4% compared to 18.2% and 20% in private
hospitals and pharmacies respectively (p = 0.203). Com-
paring private hospitals and private pharmacies, the se-
lected medicines were more available in the latter. Of
the 3 study sites categories, inhaled LABA, SAMA and
adult spacers were only available in private pharmacies
(15.3%, 18.8% and 28.2% respectively) (summarised in
Table 1). All the medicines of interest except inhaled
LABA were more available in the central region
(summarised in Table 2).
Comparison of the availability of selected diagnostic tests
in private and public hospitals
There was no documented statistically significant differ-
ence in the availability of spirometry and peak flow-
metry in private and public hospitals. Spirometry was
available in 13.6% and 34.8% of private and public hospi-
tals respectively (p = 0.099) while peak flow-metry were
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available in 4.6% and 8.7% of private and public hospitals
respectively (p = 0.577) (summarised in Table 1).
Comparison of the median cost of the lowest priced
generic and originator brand in the private hospitals and
pharmacies
With the exception of Combivent® (salbutamol/ipratro-
pium 100/20 μg soft mist inhaler), the median prices of
all originator brands were higher than the obtained me-
dian prices of the generic brands. Marked differences in
median prices were noted with formoterol/budesonide
4.5/160 μg LABA-ICS combination, ICS budesonide
200 μg and all doses of the ICS fluticasone propionate
250 μg, 125 μg and 50 μg. The cost of generic and
originator montelukast 20 mg brands were similar
(summarised in Table 3).
Table 1 Availability of the asthma-COPD drugs and diagnostic tests in private and public hospitals and private pharmacies (n = 130)
Availability (%)
A: Selected medicines (N = 10 classes and 2 types of spacers) Availability (%) in all
study sites (N = 130)
Public hospitals
(N = 23)
Private hospitals
(N = 22)
Private pharmacies
(N = 85)
P value
Inhaled LAMA monotherapies 0.0 0.0 0.0 0.0 NA
Inhaled LABA and LAMA combinations 0.0 0.0 0.0 0.0 NA
Inhaled LABA monotherapies 10.0 0.0 0.0 15.3 0.022
Inhaled SABA and SAMA combinations. 10.8 0.0 4.6 15.3 0.065
Inhaled SAMA monotherapy 12.3 0.0 0.0 18.8 0.008
Oral methylxanthines 16.9 4.0 18.2 20.0 0.203
Adult spacer devices 18.5 0.0 0.0 28.2 <0.001
Paediatric spacer devices 19.2 0.0 4.6 28.2 0.002
ICS monotherapies 45.4 4.0 50.0 55.3 <0.001
Inhaled LABA- ICS combinations 46.9 0.0 40.9 61.2 <0.001
Oral LTRA 60.8 0.0 59.1 76.7 <0.001
Inhaled SABA monotherapy 75.0 26.1 77.3 88.2 <0.001
B: Diagnostic/monitoring tests
Peak flow-metry 6.7 8.7 4.6 NA 0.577
Spirometry 24.4 34.8 13.6 NA 0.099
LAMA-Long acting anti muscarinic agents, LABA-Long acting beta agonists, SABA-Short acting beta agonists, SAMA-Short acting anti muscarinic agents, ICS-
Inhaled corticosteroids, LTRA-Leukotriene receptor antagonists
Table 2 Availability of the asthma-COPD drugs in the 4 study regions
Availability (%)
Selected medicines (N = 10 classes and 2 types of spacers) Central region Eastern region Western region Northern region P value
Inhaled LABA and LAAC combinations 0.0 0.0 0.0 0.0 NA
Inhaled LAAC monotherapies 0.0 0.0 0.0 0.0 NA
Inhaled LABA monotherapies 9.7 4.2 4.6 33.3 0.031
Inhaled SABA and SAAC combinations 19.4 0.0 0.0 0.0 0.005
Inhaled SAAC monotherapy 22.2 0.0 0.0 0.0 0.002
Oral methylxanthines 22.2 16.7 4.6 8.3 0.215
Adult spacer devices 25.0 8.3 13.6 8.3 0.184
Paediatric spacer devices 30.6 4.2 4.6 8.3 0.004
Inhaled LABA-ICS combinations 61.1 25.0 31.8 33.3 0.004
ICS monotherapies 61.1 37.5 9.1 33.3 <0.001
Oral LTRA 75.0 37.5 50.0 41.7 0.002
Inhaled SABA monotherapy 80.6 70.8 68.2 66.7 0.490
LAMA-Long acting anti muscarinic agents, LABA-Long acting beta agonists, SABA-Short acting beta agonists, SAMA-Short acting anti muscarinic agents, ICS-
Inhaled corticosteroids, LTRA-Leukotriene receptor antagonists
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Pricing and affordability of the medicines and diagnostic
tests
Selected medicines
The IPR were only available for salbutamol 100 μg in-
halers, ipratropium 20 μg inhalers, beclometasone 100 μg
inhalers, budesonide 200 μg inhalers and fluticasone pro-
pionate 125 μg. According to the calculated MPR, these
drugs were all highly priced with the local retail prices be-
ing >100 times the IRP.
Affordability of the drugs ranged from 2 days’ wages
for salbutamol 100 μg metered dose inhalers to 17 days’
wages for formoterol-budesonide 4.5/160 μg LABA-ICS
combination. According to the study definition of afford-
ability, salbutamol 100 μg MDI was the only affordable
asthma and COPD medicine. With the exception of flu-
ticasone propionate 125 μg inhalers (cost 10 days’ wages)
and budesonide 200 μg inhalers (cost 8 days’ wages), the
rest of controller or maintenance medicines cost ≤7 days’
wages.
Inhaled ipratropium either as monotherapy or in com-
bination with salbutamol as reliever medicines were
largely unaffordable, with costs of up to 8 to 14 days’
wages. Both adult and paediatric spacers were also
largely unaffordable (costs of 13 and 8 days’ wages
respectively).
(Pricing and affordability of medicines is summarised
in Table 4).
Diagnostic tests
The cost of performing spirometry was obtained from
only 2 surveyed hospitals because the other hospitals
offer it free of charge. The median cost of performing
spirometry was 130,000 UgX (36.1 USD) which trans-
lates to 27.8 days’ wages.
Discussion
Availability of the medicines and diagnostic tests
This study aimed at providing contemporary informa-
tion about the availability, cost and affordability of medi-
cines and diagnostic tests essential in asthma and COPD
management in Uganda. To our knowledge, this is the
largest study to investigate the availability, cost and af-
fordability of these essential medicines and diagnostic
tests in Uganda.
Generally, all the selected asthma and COPD medi-
cines and diagnostic tests were either of moderate or
low availability. The lowest levels of availability were in
public hospitals. The only available medicines in the
public hospitals were inhaled SABA in 26.1%, ICS and
oral methylxanthines (both in 4.4%). This low availability
of essential medicines of asthma and COPD in our study
has also been widely reported in the majority of studies
investigating access to chronic diseases medicines in
LMIC [7, 21–23] and in the annual medicine price
monitor studies in Uganda [24, 25].
In the study by Babar Z et al. performed in 52 LMIC
(Uganda inclusive) to investigate the availability, pricing
and affordability of 3 essential asthma medicines (in-
haled salbutamol, beclometasone and budesonide); gen-
eric beclometasone and budesonide were available in
only 19% and 16% of the surveyed public hospitals re-
spectively and in 46% and 58% in the private sector re-
spectively. The 2 ICS of interest were unavailable in 14
of the surveyed 52 LMIC. Generic salbutamol inhalers
were available in 56% and 82% of the public hospitals
and private pharmacies [7]. Similar findings of low avail-
ability of asthma medicines was also reported by another
cross sectional study by Cameron A et al. performed in
36 LMIC (10 sub Saharan African countries including
Table 3 Comparison of the median prices of the inhaled and oral generic and originator asthma and COPD medicine brands
Generic brands Median (IQR) price
in UgX
Median (IQR) price
in USD
Originator brands Median (IQR) price
in UgX
Median (IQR) price
in USD
Salbutamol 100 μg 10,000 (9000–13,000) 2.8 (2.5–3.6) Ventolin 100 μg 12,000 (10000–15,000) 3.3 (2.8–4.2)
Ipratropium bromide 20 μg 60,000 (48500–65,000) 16.7 (13.5–18.1) Atrovent 20 μg 62,500 (60000–65,000) 17.4 (16.7–18.1)
Ipratropium 40 μg 64,000 (56750–65,000) 17.8 (15.8–18.1) Atrovent 40 μg 65,000 (65000–70,000) 18.1 (18.1–19.4)
Salbutamol/ipratropium 100/20 μg 50,000 (35000–65,000) 13.9 (9.7–18.1) Combivent 100/20 μg 40,000 (30000–50,000) 11.1 (8.3–13.9)
Formoterol-budesonide 4.5/160 μg 80,000 (45000–85,000) 22.2 (12.5–23.6) Symbicort 4.5/160 μg 100,000 (85000–120,000) 27.8 (23.6–33.3)
Salmeterol-fluticasone propionate
25/125 μg
48,000 (35000–50,000) 13.3 (9.7–13.9) Seretide 25/125 μg 50,000 (48000–60,000) 13.9 (13.3–16.7)
Budesonide 200 μg 37,500 (33000–42,000) 10.4 (9.2–11.7) Pulmicort 200 μg 100,000 (75000–130,000) 27.8 (20.8–36.1)
Fluticasone propionate 250 μg 25,000 (25000–26,000) 6.9 (6.9–7.2) Flixotide 250 μg 87,500 (80000–95,000) 24.3 (22.2–26.4)
Fluticasone propionate 125 μg 27,000 (25000–40,000) 7.5 (6.9–11.1) Flixotide 125 μg 87,500 (87500–87,500) 24.3 (24.3–24.3)
Fluticasone propionate 50 μg 27,500 (25000–30,000) 7.6 (6.9–8.3) Flixotide 50 μg) 78,500 (78500–78,500) 21.8 (21.8–21.8)
Tablets montelukast 10 mg 1000 (800–1200) 0.3 (0.2–0.3) Singular 10 mg 1100 (900–1400) 0.3 (0.3–0.4)
Tablets montelukast 20 mg 1200 (1000–1500) 0.3 (0.3–0.4) Singular 20 mg 1200 (1100–1500) 0.3 (0.3–0.4)
IQR-Inter-quartile range, UgX-Uganda shillings, USD-US dollars
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Uganda). This study sought to assess the availability
and pricing of 30 core medicines for acute and
chronic diseases. The only surveyed asthma drug (in-
haled salbutamol 100 μg MDI) was on average avail-
able in 14% (0–55.9%) and 47% (0–95%) of the public
hospitals and private pharmacies in the 8 participating
African countries [21].
According to the medicine price monitoring study
conducted in Uganda in 2014, the availability of the only
assessed asthma medicine (salbutamol 100 μg inhaler)
was 13%, 54% and 56% in the surveyed public, private
and mission or PNFP health facilities [22]. The 2015
medicine price monitoring study noted that salbutamol
inhaler was available in <25% of the public facilities [23].
The dismal availability of asthma and COPD medi-
cines in Uganda especially in the public hospitals could
be due to the few asthma and COPD medicines included
in our essential drug list. Among the medicines of inter-
est for this study, the asthma medicines section of the
2012 Uganda essential drug list included only aminoph-
ylline tablets, beclometasone and salbutamol inhalers
[26]. These are also the only drugs recommended for
management of asthma in the 2016 Uganda clinical
guidelines (UCG). There is no recommendation for in-
haled LABA-ICS combinations, inhaled LAMA, inhaled
SAMA and oral LTRA in the management of asthma.
Despite the 2016 UCG recommendation to use ipratro-
pium inhalers and inhaled LABA in combination with
ICS in the management of COPD, both drugs were
absent in all surveyed public and private hospitals.
Ipratropium, a key SAMA was only available in private
pharmacies (18.8%).
Other essential medicines in COPD management like
inhaled LAMA (either as monotherapy/in combination
with LABA) were not available in any study site. This
could also probably be due to their absence in the
Ugandan clinical guidelines and essential drug lists. The
overall low and moderate availability of the key asthma
and COPD medicines in the study could also be ex-
plained by the evident knowledge gaps and inapt pre-
scription practices among healthcare practitioners in
Uganda with regard to asthma and COPD management.
A retrospective study evaluating asthma medication pre-
scription practices of healthcare practitioners at the
chest clinic and accident and emergency department of
a national referral hospital in Uganda noted a high fre-
quency of prescription of oral salbutamol (> 50%), oral
prednisolone (64.2%) and oral aminophylline (16%) in
the chest clinic. Inhaled beta agonists and ICS were only
used in 38% and 24% of the patients [5].
Low availability of spacers which are key in facilitating
optimal delivery of inhaled medicines in young children
Table 4 Median (IQR) prices and affordability of the lowest priced generic inhaled asthma-COPD drugs in both private hospitals and
pharmacies
Drug Median (IQR) price in Ug Shs Median local
price in USD
IRP in USD MPR Monthly
cost in USD
Days’ wages
Salbutamol 100 μg 10,000 (9000–13,000) 2.8 0.0114 243 2.8 2.2
Formoterol 12 μg. 38,500 (30000–44,000) 10.7 – – 10.7 8.2
Salmeterol 25 μg 30,000 (25500–33,750) 8.3 – – 8.3 6.4
Ipratropium bromide 20 μg 60,000 (48500–65,000) 10.7 0.0220 486 10.7 8.2
Ipratropium 40 μg 64,000 (56750–65,000) 17.8 – – 17.8 13.7
Salbutamol/ipratropium 100/20 μg 50,000 (35000–65,000) 13.9 – – 13.9 10.7
Formoterol-beclomethasone 6/100 μg 30,000 (15000–40,000) 8.3 – – 8.3 6.4
Formoterol-budesonide 4.5/160 μg 80,000 (45000–85,000) 22.2 – – 22.2 17.1
Salmeterol-fluticasone propionate 25/125 μg 48,000 (35000–50,000) 13.3 – – 13.3 10.2
Beclomethasone dipropionate 100 μg 25,000 (20000–30,000) 6.9 0.0444 155 6.9 5.3
Budesonide 200 μg 37,500 (33000–42,000) 10.4 0.0305 340 10.4 8
Fluticasone propionate 250 μg 25,000 (25000–26,000) 6.9 – – 6.9 5.3
Fluticasone propionate 125 μg 27,000 (25000–40,000) 7.5 0.0630 119 7.5 5.8
Fluticasone propionate 50 μg 27,500 (25000–30,000) 7.6 – – 7.6 5.9
Slow release theophylline tablets 100 mg 1000 (1000–1900) 0.3 – – 9 6.9
Tablets montelukast 10 mg 1000 (800–1200) 0.3 – – 9 6.9
Tablets montelukast 20 mg 1200 (1000–1500) 0.3 – – 9 6.9
Adult spacers 60,000 (51000–65,000) 16.7 – – 16.7 12.9
Paediatric spacers 35,000 (28500–45,000) 9.7 – – 9.7 7.5
IQR-Inter-quartile range, UgX-Uganda shillings, USD-US dollars, IRP-International reference price, MPR-Median price ratio
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and elderly patients with poor inspiratory effort
(<20% in all study sites) and the diagnostic tests (spir-
ometry and peak flow-metry <25% and <10% respect-
ively) was well documented in both the public and
private sector. Availability of spacers and diagnostic
tests has not been widely studied in most studies
assessing access to asthma and COPD medicines and
diagnostics in LMIC.
Affordability of the medicines and diagnostic tests
With the exception of salbutamol inhalers, the rest of the
asthma and COPD medicines were largely unaffordable
when accessed from the private sector. From the list of
medicines of interest, the cheapest inhaled LABA (salme-
terol 25 μg MDI), inhaled SAMA (ipratropium 20 μg), in-
haled SABA-SAMA combination (salbutamol/ipratropium
100/20 μg), ICS (beclometasone 100 μg /fluticasone propi-
onate 250 μg) and inhaled LABA-ICS combination
(formoterol-beclometasone 6/100 μg) would cost 6 days’
wages, 8 days’ wages, 11 days’ wages, 5 days’ wages
and 6 days’ wages of the least paid government
employee respectively. All recommended oral control-
ler therapies (methylxanthines and LTRA) would cost
about 7 days’ wages.
The cheapest standard generic asthma and COPD
treatment regimen of an inhaled SABA (used on an as
needed basis) and ICS-LABA combination would col-
lectively cost 11.1 USD which translates to 8.6 days’
wages of the least paid government employee. A com-
bination regimen of the cheapest generic SABA inhaler
(salbutamol inhaler 100 μg) and ICS (beclometasone in-
haler 100 μg) would cost 9.7 USD or 7.5 days’ wages.
A wide variation in affordability of asthma and COPD
medicines has been reported in the majority of similar
studies across different countries. In one study investi-
gating the availability and affordability of essential medi-
cines in 6 LMIC documented the cost of standard
asthma combination therapy of the lowest priced generic
salbutamol and beclometasone inhalers were 1.3 days’
wages in Bangladesh, 9.2 days’ wages in Malawi, 5.4 days’
wages in Nepal, 2.5 days’ wages in Pakistan and 2.3 days’
wages in Sri Lanka [22]. The cost of similar combination
therapy in another study performed in India was 2 days’
wages [27]. Salbutamol inhaler remains affordable in
Uganda. The 2014 and 2015 medicine price monitor
studies performed in Uganda reported the cost of only
salbutamol 100 μg inhaler of 1.4 and 1.6 days’ wages re-
spectively [24, 25] compared to 2.2 days wages’ in our
study. Other asthma and COPD drugs were not studied.
The majority of asthma and COPD medicines being un-
affordable in the private sector in this study could prob-
ably be explained by the lack of a national policy or
legislation to regulate retail prices of medicines especially
for chronic diseases. Uganda also lacks a vibrant local
pharmaceutical industry sector that would manufacture
cheap quality generic asthma and COPD medicines for
the public and private sector.
There is paucity of studies investigating the cost and
affordability of performing spirometry in LMIC. The
cost equivalent to 27.8 days’ wages reported by our study
findings is unaffordable to the majority of Ugandan pa-
tients with asthma and COPD. This could be due to the
limited hospitals and expertise capable of rendering this
specialist service.
Conclusions
This study demonstrated that the majority of asthma
and COPD medicines and diagnostic tests were largely
unavailable especially in the public hospitals and un-
affordable in the private sector. In the public sector,
inequity in access to medicines and diagnostic tests for
asthma and COPD care can be addressed through in-
creased awareness about optimal management of asthma
and COPD among healthcare practitioners and patients,
inclusion of other essential asthma and COPD medicines
on the national essential drug list and clinical care
guidelines, improving forecast accuracy, procurement
efficiency and stock handling and boosting local produc-
tion of cheap quality generic asthma and COPD medi-
cines. At the private sector level, access to affordable
medicines can be improved through implementation of
national policies aimed at regulating retail prices of med-
icines especially for chronic care, improving forecast
accuracy, procurement efficiency, stock handling and
local production of cheap generic medicines. Due to the
prohibitive costs of diagnosis and management of
asthma and COPD in Uganda, national primary preven-
tion strategies for chronic respiratory diseases should be
widely implemented to reduce the disease burden.
Study limitations
The data was collected at one point in time which does
not put into consideration the temporal variations in
availability and prices of medicines over time in the dif-
ferent surveyed hospitals and private pharmacies hence,
we cannot establish a causal relationship between the
investigated outcome of interest and the risk factors.
Misreporting (under-or over-reporting) of the data is
highly possible due to selection, information or recall
bias and the one point in time approach of data
collection.
Assessment of drug stock records was not performed
to ascertain availability of drugs. We were unable to ob-
tain the national procurement or tender prices of the
mandated government institution (NMS) to procure
and supply medicines to all government hospitals.
These would accurately reflect the prices of the few
drugs procured for the public hospitals in comparison
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the private hospitals and pharmacies. Using the daily
wage of the lowest paid unskilled government to calcu-
late affordability of medicines and diagnostic tests has
its limitations because a significant proportion of the
Ugandan population earns less than 1.3 USD per day.
Despite these limitations, the standardised WHO/HAI
methodology that was used has been widely validated.
This is the largest study to comprehensively assess the
availability and affordability of several locally and inter-
nationally guideline recommended inhaled and oral
asthma and COPD medicines and diagnostic tests in
Uganda.
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